皮膚・軟部組織感染症の世界市場：2024～2031年

世界の皮膚・軟部組織感染症の市場規模は、2023年に112億8,371万米ドルに達し、2024～2031年の予測期間中にCAGR 8.8%で成長し、2031年には217億855万米ドルに達すると予測されています。

皮膚・軟部組織感染症（SSTI）は、皮膚、筋肉、靭帯や腱などの結合組織の感染症です。SSTIの最も頻繁な原因は細菌で、火傷、小さな切り傷、擦り傷、手術部位の傷口など、さまざまな傷口から体内に侵入します。

一般的な単純性SSTIには、蜂窩織炎、丹毒、膿痂疹、毛包炎、疔、癰、膿瘍、外傷関連感染症などがあります。複雑な感染症には、深在性膿瘍、褥瘡、壊死性筋膜炎、フルニエ壊疽、人や動物の咬傷による感染症などがあります。

市場力学：

促進要因と抑制要因

製品開発と承認の増加

皮膚・軟部組織感染症治療薬の発展と承認は、市場成長の原動力になると予想されます。新薬の開発により、感染症患者のために利用可能な幅広い製品が登場します。これにより、治療用の新製品に対する需要が高まります。

広範な用途を持つ製品承認の増加は、薬剤の需要を増加させると予想されます。例えば、2024年4月、米国食品医薬品局はゼブテラ（注射用セフトビプロレメドカリルナトリウム）を、右側感染性心内膜炎を含む成人の黄色ブドウ球菌血流感染症（菌血症）（SAB）、成人の急性細菌性皮膚・皮膚構造感染症（ABSSSI）の治療薬として承認しました。

さらに、2021年7月23日、AbbVieは、出生時からの小児患者における急性細菌性皮膚・皮膚構造感染症（ABSSSI）の治療薬として、DALVANCE（一般名：ダルババンチン）の米国食品医薬品局（FDA）承認を取得しました。DALVANCEは、メチシリン耐性黄色ブドウ球菌（MRSA）による感染症を含む、小児患者における指定感受性グラム陽性菌によるABSSSIの治療において、30分の点滴静注として投与される初めての単回投与選択肢です。したがって、上記の要因が市場の成長を促進する可能性があります。

新型感染菌への耐性

バンコマイシン耐性腸球菌（VRE）やメチシリン耐性黄色ブドウ球菌（MRSA）などの抗生物質耐性菌の出現は、SSTIの治療に大きな障害となっています。このため、従来の抗生物質の有効性が低下し、治療期間の延長、医療費の増加、患者の転帰の悪化につながっています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 製品開発と承認の増加
  • 抑制要因
    • 新種の感染性細菌に対する耐性
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 償還分析
• 特許分析
• SWOT分析
• DMIオピニオン

第6章 タイプ別

• 感染性潰瘍
• 創傷感染
• 膿瘍
• 蜂巣炎
• 外耳炎
• その他

第7章 薬剤タイプ別

• 抗生物質
• 抗真菌剤
• その他

第8章 投与経路別

• 局所
• 経口
• 非経口

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• 合併・買収分析

第12章 企業プロファイル

• GSK Plc
• Pfizer Inc.
• Merck KGaA
• Wellona Pharma
• GL Pharma
• Basilea Pharmaceutica AG
• Invision Medi Sciences Pvt. Ltd.
• Intelicure Lifesciences.
• Steris Healthcare Pvt Ltd
• SNU Biocare（*LIST NOT EXHAUSTIVE）

第13章 付録

Market Overview

The Global Skin and Soft Tissue Infections Market reached US$ 11,283.71 million in 2023 and is expected to reach US$ 21,708.55 million by 2031, growing at a CAGR of 8.8% during the forecast period 2024-2031.

Skin and Soft Tissue Infections (SSTI) are infections of the skin, muscles, and connective tissue such as ligaments and tendons. The most frequent cause of SSTIs is bacteria, which can enter the body through a variety of openings such as burns, tiny cuts, scrapes, and wounds from surgical sites.

Common simple SSTIs include cellulitis, erysipelas, impetigo, ecthyma, folliculitis, furuncles, carbuncles, abscesses, and trauma-related infections. Complicated infections include deep abscesses, decubitus ulcers, necrotizing fasciitis, Fournier gangrene, and infections from human or animal bites.

Market Dynamics: Drivers & Restraints

Rising product development and approvals

The rising developments and approvals of the drugs for the treatment of Skin and Soft Tissue Infections is expected to drive the market growth. With the development of new drugs there will be a wide range of products available for the individuals with the infections. This rises the demand for the new products for the treatment.

The rising product approvals with broad spectrum applications is expected to increase the demand for the drugs. For instance, in April 2024, the U.S. Food and Drug Administration approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis, adults with acute bacterial skin and skin structure infections (ABSSSI).

Additionally, July 23, 2021, AbbVie received the U.S. Food and Drug Administration (FDA) approved DALVANCE (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth. DALVANCE is the first single-dose option administered as a 30-minute intravenous (IV) infusion for the treatment of ABSSSI caused by designated susceptible Gram-positive bacteria in pediatric patients, including infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Thus, the above factors could drive the market growth.

Resistance to the new strains of infectious bacteria

The emergence of antibiotic-resistant bacteria, such as vancomycin-resistant Enterococcus (VRE) and methicillin-resistant Staphylococcus aureus (MRSA), presents a major obstacle to the treatment of SSTIs. This reduces the effectiveness of conventional antibiotics, leading to extended therapy times, higher medical expenses, and worse patient outcomes.

Segment Analysis

The global Skin and Soft Tissue Infections market is segmented based on type, drug type, route of Administration, distribution channel and region.

Antibiotics segment is expected to dominate the market share

Antibiotics segment holds a major position in the market share. For bacterial SSTIs, antibiotics are currently the primary form of treatment. They function well against a variety of bacterial pathogens, including Streptococcus pyogenes and Staphylococcus aureus, that can lead to skin infections. Antibiotics specifically target bacterial infections, that are a common cause of SSTIs.

The large number of prescriptions for and treatments for bacterial infections has created an significant position for antibiotics.

The market position of antibiotics is further built by ongoing research and development activities in antibiotic therapy, which lead to the creation of novel formulations, combinations, and enhanced efficacy against antibiotic-resistant bacteria. Thus, the above factors are expected to drive the segment growth.

Geographical Analysis

North America is expected to hold a significant position in the skin and soft tissue infections market share

North America is holding a dominant position in the market share owing to the increasing incidence of several Skin and Soft Tissue Infections in the region. The presence of a large number of pharmaceutical companies in the region is also expected to be a factor in the growth of the region's market.

The region has an advanced healthcare infrastructure with established hospitals and clinics. The hospitals and clinics have well-established diagnostic tools and the region also has well-established medical research and advancements in treatment options.

The increasing number of Skin and Soft Tissue Infections in the region increases demand for the new drugs that are developed in the region. For instance, according to the report by NIH in 2023, it is estimated that cellulitis is a very common skin infection that accounts for more than 14 million cases in the United States per year.

Additionally, according to the Agency for Healthcare Research and Quality, each year, more than 2.5 million people in the United States develop pressure ulcers. These skin lesions bring pain, associated risk for serious infection, and increased health care utilization. Pressure ulcers are associated with longer hospital stays and increased morbidity and mortality. Thus, the above factors are expected to hold the region in the dominant position.

Market Segmentation

By Type

Infected Ulcers

Wound Infections

Abscesses

Cellulitis

Otitis Externa

Others

By Drug Type

Antibiotics

Anti-fungal Agents

Others

By Route of Administration

Topical

Oral

Parenteral

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Others

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Competitive Landscape

The major global players in the market include GSK Plc, Pfizer Inc., Merck KGaA, Wellona Pharma, GL Pharma, Basilea Pharmaceutica AG, Invision Medi Sciences Pvt. Ltd., Intelicure Lifesciences., Steris Healthcare Pvt Ltd and SNU Biocare among others.

Why Purchase the Report?

To visualize the global skin and soft tissue infections market segmentation based on type, drug type, route of administration, distribution channel, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of skin and soft tissue infections market-level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as Excel consisting of key products of all the major players.

The global skin and soft tissue infections market report would provide approximately 53 tables, 47 figures, and 176 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Drug Type
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising product development and approvals
  • 4.1.2. Restraints
    • 4.1.2.1. Resistance to the new strains of infectious bacteria
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis
• 5.6. Patent Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Infected Ulcers*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Wound Infections
• 6.4. Abscesses
• 6.5. Cellulitis
• 6.6. Otitis Externa
• 6.7. Others

7. By Drug Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 7.1.2. Market Attractiveness Index, By Drug Type
• 7.2. Antibiotics*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Anti-fungal Agents
• 7.4. Others

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Topical*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Oral
• 8.4. Parenteral

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. UK
    • 10.3.7.3. France
    • 10.3.7.4. Italy
    • 10.3.7.5. Spain
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. GSK Plc*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Pfizer Inc.
• 12.3. Merck KGaA
• 12.4. Wellona Pharma
• 12.5. GL Pharma
• 12.6. Basilea Pharmaceutica AG
• 12.7. Invision Medi Sciences Pvt. Ltd.
• 12.8. Intelicure Lifesciences.
• 12.9. Steris Healthcare Pvt Ltd
• 12.10. SNU Biocare (*LIST NOT EXHAUSTIVE)

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us